CMCaroline Mayeur-Rousse

Caroline Mayeur-Rousse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caroline Mayeur-Rousse has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Daratumumab in Combination With High‐Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T‐Cell Acute Lymphoblastic Leukemia: A Case Report

    by Perrine Moyer, Baptiste Le Calvez, Caroline Mayeur‐Rousse, Audrey Grain

    Patients with refractory or relapsed T‐cell acute lymphoblastic leukemia (R/R T‐ALL) have dismal outcomes. While immunotherapies are growing opportunities for B‐cell ALL, targeted therapies for T‐ALL remain limited. The CD38 antigen, steadily expressed on T‐ALL blasts, represents a relevant therapeutic target. Daratumumab, an anti‐CD38 monoclonal antibody routinely used in other hematologic malignancies, could be a promising treatment option for T‐ALL. We report here the achievement of a third complete response with the combination of daratumumab, high‐dose cytarabine (18 g/m 2 ), and amsacrine in an 11‐year‐old patient with highly aggressive relapsed T‐ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.

  • Open Access

    Artificial intelligence–based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders

    by Laurent Mauvieux, Raoul Herbrecht, Alice Eischen, Anne-Cécile Galoisy, Delphine Rolland, Carine Gervais, Caroline Mayeur-Rousse, Sarah Hueber-Bonnot, Alina Nicolae, Luc-Matthieu Fornecker, et al.

    Accurate diagnosis of B-cell chronic lymphoproliferative disorders (B-CLPDs) remains challenging due to overlapping phenotypes across subtypes. Machine learning (ML) offers promising tools to improve marker evaluation and refine flow cytometry analysis. We investigated the use of ML algorithms to evaluate the diagnostic value of incorporating CD148, CD180, and CD200 into standard B-CLPD phenotyping panel and to develop a diagnosis decision tree. We trained models with flow cytometry data from 480 patients with B-CLPDs using XGBoost and DecisionTree algorithms. The final models integrated 2 categorical markers (CD5 and CD10) and quantiles of fluorescence intensity of 4 quantitative markers (CD20, CD180, and CD200) to classify 6 B-CLPD subtypes. These trained models were applied to an independent cohort of 433 patients with B-CLPD analyzed on a different flow cytometer platform. DecisionTree models achieved the highest classification accuracy (mean accuracy, 0.88) in the validation cohort. The overall specificity ranged from 0.95 lymphoplasmacytic lymphoma (LPL) to 1 hairy cell leukemia (HCL), whereas sensitivity varied from 0.75 (LPL) to 1 (HCL). The DecisionTree model demonstrated superior identification of chronic lymphocytic leukemia compared to a Matutes score of 4 or 5 (P = .029). In more than half of the cases, a diagnosis was determined with near certainty using only the cytometry data. For the remaining cases, a hierarchical approach incorporating additional tests was proposed. For practical implementation, an interactive interface provides diagnostic predictions, positive predictive values, and Gini index scores. This study establishes a ML-optimized strategy for B-CLPD classification, combining phenotypic, cytogenetic, and molecular data to enhance diagnostic accuracy of leukemic B-CLPD cells. This trial was registered at www.ClinicalTrials.gov as #NCT04952974.